• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study

    Gabrielle Lakusta
    Jan. 18, 2019 08:45AM PST
    Biotech Investing

    Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced pancreatic cancer demonstrated substantially improved survival benefit compared to expected median overall survival outcomes. As quoted in the press release: “We have no real options …

    Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced pancreatic cancer demonstrated substantially improved survival benefit compared to expected median overall survival outcomes.

    As quoted in the press release:

    “We have no real options for treating end-of-life patients with advanced pancreatic cancer,” said Dr. Vincent Picozzi, Director of the Pancreaticobiliary Program at the Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Principal Investigator in the Tyme Phase II metastatic pancreatic cancer trial, and a Precision Promise Committee Chair. “The current survival when considering the safety of SM-88, offers new hope to both patients and physicians seeking viable treatment options for advanced patients.”

    SM-88 was well tolerated with only 2 (6.5%) serious adverse events (SAEs) deemed at least potentially-related to SM-88.  These SAEs both occurred in one patient, who continued on SM-88 treatment.

    The 88-Panc results are from an investigational study. SM-88 is not approved for the treatment of patients with advanced pancreatic cancer.

    Click here to read the full press release.

    tyme technologiesnasdaq:tyme
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×